Next Article in Journal
Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib
Previous Article in Journal
Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4130
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma

by
C. Sakaguchi
1,
K. Ashida
1,2,*,
S. Yano
1,
K. Ohe
3,
N. Wada
4,
N. Hasuzawa
1,2,
Y. Matsuda
1,
S. Sakamoto
1,
R. Sakamoto
1,
H. Uchi
4,
M. Furue
4,
M. Nomura
1,2 and
Y. Ogawa
1
1
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan
2
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
3
Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka City, Japan
4
Department of Dermatology, Kyushu University Hospital, Fukuoka City, Japan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 115-118; https://doi.org/10.3747/co.26.4130
Submission received: 8 November 2018 / Revised: 12 December 2018 / Accepted: 12 January 2019 / Published: 1 February 2019

Abstract

Nivolumab, an anti–PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Another endocrinopathy is nivolumab-induced type 1 diabetes mellitus (T1DM), described as diabetes mellitus with rapid onset and complete insulin insufficiency, at times leading to fulminant T1DM. We report the case of a 68-year-old woman who developed pancreatic islet–related autoantibody-negative T1DM, possibly induced by nivolumab, under continuous glucocorticoid administration. She was treated with nivolumab for advanced malignant melanoma, concomitant with 10 mg prednisolone daily for thrombophlebitis tapered to 5 mg after 13 courses of nivolumab therapy. At approximately the 27th course of nivolumab therapy, she showed elevated plasma glucose levels despite preserved insulin secretion. A month later, she developed diabetic ketoacidosis. Her insulin secretion decreased and finally was exhausted. She was diagnosed with acute-onset rather than fulminant T1DM because of a rapidly progressive course to diabetic ketoacidosis during just more than 1 week. She is currently receiving insulin replacement. There has been no recurrence of the melanoma. Thus, nivolumab might induce autoimmune diabetes mellitus, with patients having T1DM-sensitive human leucocyte antigen being more susceptible even when receiving glucocorticoids. Physicians should be aware that nivolumab could potentially induce T1DM as a critical immune-related adverse event.
Keywords: melanoma; nivolumab; autoimmunity; adverse drug events; diabetes mellitus; type 1 diabetes melanoma; nivolumab; autoimmunity; adverse drug events; diabetes mellitus; type 1 diabetes

Share and Cite

MDPI and ACS Style

Sakaguchi, C.; Ashida, K.; Yano, S.; Ohe, K.; Wada, N.; Hasuzawa, N.; Matsuda, Y.; Sakamoto, S., 1; Sakamoto, R.; Uchi, H.; et al. A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma. Curr. Oncol. 2019, 26, 115-118. https://doi.org/10.3747/co.26.4130

AMA Style

Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N, Matsuda Y, Sakamoto S 1, Sakamoto R, Uchi H, et al. A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma. Current Oncology. 2019; 26(1):115-118. https://doi.org/10.3747/co.26.4130

Chicago/Turabian Style

Sakaguchi, C., K. Ashida, S. Yano, K. Ohe, N. Wada, N. Hasuzawa, Y. Matsuda, S. Sakamoto 1, R. Sakamoto, H. Uchi, and et al. 2019. "A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma" Current Oncology 26, no. 1: 115-118. https://doi.org/10.3747/co.26.4130

APA Style

Sakaguchi, C., Ashida, K., Yano, S., Ohe, K., Wada, N., Hasuzawa, N., Matsuda, Y., Sakamoto, S., 1, Sakamoto, R., Uchi, H., Furue, M., Nomura, M., & Ogawa, Y. (2019). A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma. Current Oncology, 26(1), 115-118. https://doi.org/10.3747/co.26.4130

Article Metrics

Back to TopTop